Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Comment by MementoMorion Jun 11, 2008 4:42pm
253 Views
Post# 15174169

RE: for fun : count the chicken

RE: for fun : count the chicken> before they hatch.......a 100 million cash deal for both Psoriasis andtransplant indications...excluding equity investment in the company....

The deal already in place for transplant alone (the deal that Roche can only take or leave) is worth much more than $100 million. Roche has to pay $75 million immediately upon acceptance, be responsible for 70% of all future development costs for transplant (which cost $++), and make already-negotiated milestone payments that add up, if I recall correctly, to somewhere over $200 million.

For those keeping score, $75 million in cash is $0.71 per share. If you think Roche will opt in, we are now trading, when we add in ISA's admittedly-slim current cash reserves, only a few cents above the company's cash value when they do.

Bullboard Posts